148 related articles for article (PubMed ID: 31210664)
21. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
Adam MA; Nassour I; Hoehn R; Hlavin CA; Bahary N; Bartlett DL; Lee KKW; Zureikat AH; Paniccia A
Ann Surg Oncol; 2021 Jul; 28(7):3800-3807. PubMed ID: 33386547
[TBL] [Abstract][Full Text] [Related]
22. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
23. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
24. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
25. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment.
You MS; Lee SH; Choi YH; Shin BS; Paik WH; Ryu JK; Kim YT; Jang DK; Lee JK; Kwon W; Jang JY; Kim SW
BMC Cancer; 2019 Oct; 19(1):952. PubMed ID: 31615457
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
28. Reappraisal of Nodal Staging and Study of Lymph Node Station Involvement in Pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer.
Malleo G; Maggino L; Capelli P; Gulino F; Segattini S; Scarpa A; Bassi C; Butturini G; Salvia R
J Am Coll Surg; 2015 Aug; 221(2):367-79.e4. PubMed ID: 26081176
[TBL] [Abstract][Full Text] [Related]
29. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma?
Hakeem AR; Marangoni G; Chapman SJ; Young RS; Nair A; Hidalgo EL; Toogood GJ; Wyatt JI; Lodge PA; Prasad KR
Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):1047-54. PubMed ID: 25051217
[TBL] [Abstract][Full Text] [Related]
30. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy.
Zehnder P; Studer UE; Daneshmand S; Birkhäuser FD; Skinner EC; Roth B; Miranda G; Burkhard FC; Cai J; Skinner DG; Thalmann GN; Gill IS
BJU Int; 2014 Apr; 113(4):554-60. PubMed ID: 24131453
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
33. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
34. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
[TBL] [Abstract][Full Text] [Related]
35. Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.
O'Shea AE; Bohan PMK; Carpenter EL; McCarthy PM; Adams AM; Chick RC; Bader JO; Krell RW; Peoples GE; Clifton GT; Nelson DW; Vreeland TJ
Ann Surg Oncol; 2022 Sep; 29(9):6015-6028. PubMed ID: 35583691
[TBL] [Abstract][Full Text] [Related]
36. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.
Fischer LK; Katz MH; Lee SM; Liu L; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Roland CL; Fleming JB; Estrella J; Rashid A; Wang H
Histopathology; 2016 Jan; 68(2):210-20. PubMed ID: 25945396
[TBL] [Abstract][Full Text] [Related]
37. Evolution and impact of lymph node dissection during pancreaticoduodenectomy for pancreatic cancer.
Eskander MF; de Geus SW; Kasumova GG; Ng SC; Al-Refaie W; Ayata G; Tseng JF
Surgery; 2017 Apr; 161(4):968-976. PubMed ID: 27865602
[TBL] [Abstract][Full Text] [Related]
38. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
Mariette C; Piessen G; Briez N; Triboulet JP
Ann Surg; 2008 Feb; 247(2):365-71. PubMed ID: 18216546
[TBL] [Abstract][Full Text] [Related]
39. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
40. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
